Summary
ImmunityBio is a clinical-stage biotech developing cancer immunotherapies. Its stock is a high-risk bet on unproven science, trading at 194x sales despite minimal revenue. While recent trial news is encouraging, the financials show unsustainable cash burn and reliance on speculative outcomes.
Bull Case
ImmunityBio could revolutionize cancer treatment with its cell therapy platform. Successful Phase 1 data for CD19 t-haNK in 2025 may trigger partnerships or buyout interest, justifying today’s high valuation. Revenue from early-stage trials ($14.7M in 2024) shows growing research collaborations.
Bear Case
The company has no approved products and burns $300M+ annually. With only $143M cash (Q4-2024), it may need dilutive financing within 6 months. A failed trial could erase 50%+ of market cap, as seen in volatile biotech stocks.
Recent News
- FY 2024 Results (Mar 2025): Revenue grew to $14.7M (from $0.6M in 2023), but missed estimates by 31%. Net loss narrowed to $413.6M. EPS improved to -$0.59 vs. -$1.15 in FY 2023.
- Phase 1 Trial Launch (Mar 2025): Stock surged 56% on CD19 t-haNK cell therapy trial news targeting non-Hodgkin lymphoma in South Africa (enrollment planned through early 2025).
- Promising Cancer Stock (Mar 2025): Ranked among top cancer stocks by hedge funds due to pipeline targeting global oncology markets.
Financial Analysis
- Revenue Growth: Annual revenue grew 2,270% YoY to $14.74M (2024), but Q4-2024 sequential growth slowed to 23.7% from 483% in Q3.
- Loss Narrowing: FY 2024 net loss improved 29% YoY to -$413.6M. Quarterly losses remain elevated (-$59.2M in Q4-2024).
- Cash Burn: Operating cash flow worsened to -$391.2M (2024) vs. -$366.8M (2023). Cash reserves fell to $143.4M (Q4-2024) from $265.5M (Q4-2023).
- Valuation: Extreme P/S ratio of 194.5 (Mar 2025) reflects speculative pricing despite minimal revenue.
- Liquidity: Current ratio of 3.36 (Q4-2024) remains strong, but cash burn raises sustainability concerns.
- Profitability: Gross margin at 100% (2024) suggests no COGS, typical for pre-revenue biotech. Operating margin improved to -23.3% (2024) vs. -581% (2023).
ImmunityBio is a high-risk biotech bet. While revenue growth and loss reduction signal progress, extreme valuation multiples and negative profitability metrics indicate dependence on speculative pipeline success. The 56% stock surge on trial news highlights market sensitivity to clinical milestones.
Screener Ratings
Compare over 5500 companies with our screener ratings at AIpha.io.
Overall: 4
High-risk, high-reward speculative play. Suitable only for investors comfortable with binary clinical trial outcomes.
Value: 2
Extreme P/S ratio (194.5) and negative book value (-$0.57/share) suggest overvaluation unless pipeline succeeds.
Growth: 7
Revenue grew 2,270% YoY (2024), and Phase 1 trial momentum offers optionality.
Dividend: 1
No dividends; company is pre-revenue and loss-making.
Defensive: 3
Biotech volatility makes it unsuitable for downturns, though cancer treatment demand is resilient.
Moat: 3
Pipeline patents offer potential, but no commercial moat yet.
S.W.O.T. Analysis
Strengths:
- Promising pipeline (CD19 t-haNK, QUILT trials)
- High insider ownership (alignment with shareholders)
Weaknesses:
- Negative equity (-$489.1M as of Q4-2024)
- Dependence on capital markets for funding
Opportunities:
- Partnerships/Buyouts if trials succeed
- Expansion into emerging markets (e.g., South Africa trial)
Threats:
- Clinical trial failures
- Dilution risk from future equity raises
Industry Overview
Threat of New Competitors: High barriers (R&D costs, regulatory hurdles) protect incumbents, but biotech startups with novel therapies can disrupt.
Competition Among Existing Firms: Intense (oncology sector has giants like Merck, Roche). Differentiation through niche cell therapies is critical.
Suppliers’ Bargaining Power: Moderate (specialized equipment/raw materials), but biotechs often vertically integrate R&D.
Buyers’ Bargaining Power: High (payers like insurers demand efficacy data; patients lack alternatives in late-stage cancer).
Threat of Substitute Products: High (multiple immunotherapy approaches exist, e.g., CAR-T, checkpoint inhibitors).
Competitive Advantage
Cost Advantage: None evident; R&D costs are high with no commercialized products.
Intangible Assets: Potential via patents (CD19 t-haNK platform) but unproven in late-stage trials.
Network Effect: None in biotech R&D.
Switching Costs: Low (oncologists adopt therapies with best trial data).
Warning: This document has been generated by an advanced customised AI prompted with financial data derived from company filings and other reputable sources. The process is specifically designed to minimise hallucinations, however the output is not 100% reliable. It is essential to check any information in this document before relying on it for financial decisions. You can find the underlying data used here.
Legal Disclaimer
The information contained on this website and associated documents, including all text, data, analyses, opinions, and forward-looking statements, is provided solely for general informational purposes and does not constitute financial, investment, legal, or tax advice. The content has been generated by an artificial intelligence tool using publicly available data and company filings. Although every effort has been made to ensure accuracy, the information is provided “as is” without any warranty—express or implied—of completeness, accuracy, reliability, or suitability for any purpose.
Not Regulated Advice
No FCA Authorization: We are not authorized or regulated by the Financial Conduct Authority (FCA) or any other financial regulatory body to offer investment advice or recommendations. Nothing in this report should be construed as a solicitation, recommendation, or endorsement to buy, sell, or hold any security or financial instrument.
Independent Decision-Making: Investors are strongly encouraged to conduct their own research and consult with a licensed financial advisor or other professional before making any financial decisions. Reliance on the information provided herein is solely at your own risk.
Forward-Looking Statements
This report may contain forward-looking statements, which are based on current expectations, assumptions, and projections that involve risks and uncertainties. Actual results may differ materially from those expressed or implied by these statements. We do not undertake any obligation to update or revise any forward-looking statements in light of new information or future developments.
Limitation of Liability
Under no circumstances shall Aipha.io or its affiliates, employees, or agents be liable for any direct, indirect, incidental, consequential, or other damages arising out of or in connection with the use of, or reliance on, the information contained in this report—even if advised of the possibility of such damages. This includes, without limitation, any loss of profit, revenue, or data.
Use at Your Own Risk
By using this report, you acknowledge that you have read and understood this disclaimer and agree that any reliance on the information provided is at your own risk. [Your Company Name/Aipha.io] expressly disclaims any and all liability for any loss or damage of any kind incurred as a result of any use of this report.